Trevena Inc (TRVN) 6.39 $TRVN Biotechnology Stocks in

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Trevena Inc (TRVN) 6.39 $TRVN

Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Wed Jun 22, 7:20AM CDT
On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad based as five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by accessing their free trade alerts at:
TRVN: 6.39 (+0.12), PTLA: 26.68 (+0.72), ANTH: 3.05 (-0.03), NERV: 11.18 (+0.08)

Trevena to Present at the JMP Life Sciences Conference
BusinessWire - Thu Jun 16, 3:01PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that its chief medical officer, David Soergel, M.D., will present a company overview at the JMP Life Sciences Conference on June 21st at 2:00p.m. EDT in New York.
TRVN: 6.39 (+0.12)

Trevena, Inc. Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain
BusinessWire - Wed Jun 08, 6:00AM CDT
--- Top-line data for both studies expected in 1Q 2017 -
TRVN: 6.39 (+0.12)

Trevena to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Wed Jun 01, 3:01PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that chief executive officer Maxine Gowen, Ph.D., will present a company overview at the Jefferies 2016 Healthcare Conference on June 8th at 11:00 a.m. EDT in New York.
TRVN: 6.39 (+0.12)

The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
MDVN: 64.08 (+0.09), TTPH: 4.19 (+0.17), TRVN: 6.39 (+0.12), ADRO: 14.84 (+0.16), ANAC: 99.06 (-0.14)

Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 64.08 (+0.09), TRVN: 6.39 (+0.12), TTPH: 4.19 (+0.17), VRTX: 98.20 (+1.20), ADRO: 14.84 (+0.16), AMGN: 174.16 (+2.13), ANAC: 99.06 (-0.14)

Trevena (TRVN) Down on Negative Phase IIb Data on TRV027
Zacks Equity Research - Zacks Investment Research - Tue May 17, 8:43AM CDT
Trevena (TRVN) reported disappointing data from a phase IIb study on TRV027, which failed to meet either the primary or secondary endpoints.
TRVN: 6.39 (+0.12), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)

Apple, Anacor and Tribune Publishing climb, Trevena skids
AP - Mon May 16, 3:21PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday:
TRVN: 6.39 (+0.12), TPUB: 13.96 (+0.17), MCK: 192.09 (-2.47), PFE: 37.31 (+0.42), MRD: 14.51 (-0.47), TEX: 23.75 (-0.39), ANAC: 99.06 (-0.14), MRO: 12.92 (-0.72), AAPL: 106.05 (+1.84)

Trevena Reports TRV027 Did Not Achieve Primary or Secondary Endpoints in BLAST-AHF Phase 2b Trial in Acute Heart Failure
BusinessWire - Mon May 16, 6:00AM CDT
Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company's TRV027 failed to meet either the primary or secondary endpoints in the Phase 2b BLAST-AHF study in acute heart failure (AHF). The company expects to focus its efforts on its lead Phase 3 oliceridine pain program and its earlier stage programs.
TRVN: 6.39 (+0.12)

Trevena Announces Presentations at the 35th Annual Scientific Meeting of the American Pain Society
BusinessWire - Wed May 11, 3:30PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the Company will present five posters the 35th Annual Scientific Meeting of the American Pain Society being held at the Austin Convention Center in Austin, Texas, May 11-14, 2016. The poster presentations highlight data on oliceridine, which has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration.
TRVN: 6.39 (+0.12)

Trevena reports 1Q loss
Automated Insights - Thu May 05, 6:44AM CDT
KING OF PRUSSIA, Pa. (AP) _ Trevena Inc. (TRVN) on Thursday reported a loss of $17.8 million in its first quarter.
TRVN: 6.39 (+0.12)

Trevena Reports First Quarter 2016 Financial Results and Provides Corporate Update
BusinessWire - Thu May 05, 6:00AM CDT
--- Oliceridine pivotal Phase 3 efficacy studies expected to begin this quarter -
TRVN: 6.39 (+0.12)

Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine
BusinessWire - Mon May 02, 3:01PM CDT
--- Phase 3 program includes comparisons to both placebo and morphine -
TRVN: 6.39 (+0.12)

Trevena Announces BLAST-AHF Phase 2b Trial Results will be Presented at the Heart Failure 2016 Conference
BusinessWire - Fri Apr 15, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that results from its BLAST-AHF Phase 2b study of TRV027 in acute heart failure (AHF) will be presented at Heart Failure 2016, the annual congress of the Heart Failure Association of the European Society of Cardiology. Heart Failure 2016 includes the 3rd World Congress on Acute Heart Failure, and is taking place in Florence, Italy, May 21-24, 2016.
TRVN: 6.39 (+0.12)

Trevena to Present at the Needham & Company 15th Annual Healthcare Conference
BusinessWire - Thu Apr 07, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will be webcasting its corporate presentation at the Needham & Company 15th Annual Healthcare Conference on Wednesday, April 13, 2016 at 10:00 a.m. EDT in New York.
TRVN: 6.39 (+0.12)

Trevena Announces Presentations at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting
BusinessWire - Thu Mar 31, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the Company will present four posters at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting, being held at The Roosevelt Hotel, 123 Baronne Street, New Orleans, LA from Thursday, March 31, 2016 through Saturday, April 2, 2016. The poster presentations highlight data from the oliceridine program, including key data from the Company's Phase 2b trial in acute pain following abdominoplasty.
TRVN: 6.39 (+0.12)

Trevena Reports Full Year 2015 Financial Results
BusinessWire - Wed Mar 09, 6:00AM CST
--- Net loss for the year of $50.5 million, or $1.15 per share -
TRVN: 6.39 (+0.12)

Zika Virus and Potential Effect on Olympics
ACCESSWIRE - Wed Feb 10, 8:01AM CST
BiotechMarketReport.com identifies PositiveID Corporation (PSID) as a Solution
TRVN: 6.39 (+0.12), XNCR: 19.35 (+0.41), PDLI: 3.55 (+0.03)

Trevena to present at the 18th Annual BIO CEO & Investor Conference
BusinessWire - Wed Feb 03, 3:01PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company will be webcasting its corporate presentation at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 at 4:30 p.m. EST in New York.
TRVN: 6.39 (+0.12)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 111

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Kos & FORTH Partner to Spark Greek Biotech Growth

Updated Category News Views 81

New Frontiers: Greece on the Biotech Map Partnerships in biotech aren't tossed out willy-nilly; they're crafted for precision much like a sculptor shaping marble. Kos Biotechnology Partners and the Foundation for Research and Technology-Hellas (FORTH) are doing exactly that, teaming up to birth a biotechnology incubator on the FORTH campus in Heraklion, Crete. Now tell...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 161

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 99

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 210

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
NeuroPace Faces Investigation After Revenue Forecast Cut

Updated Category News Views 35

NeuroPace Revenue Drama: A Blow to Investor Confidence How the mighty have stumbled—or so it feels to the folks who put their bucks into NeuroPace, Inc. (NASDAQ: NPCE). It's tough to swallow: they cut their 2026 revenue forecast from a hopeful $99.5-$101.5 million to a sobering $91-$92 million. Just one quarter apart those projections are, like a cruel twist of fate...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 128

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Investors, Portillo's Fraud Claims Demand Your Attention

Updated Category News Views 71

Portillo's Investors Caught in a Tough Spot Ah, Portillo's. You thought those hot dogs were the only spicy thing you're biting into? Try these allegations on for size. Investors are biting back with a securities fraud lawsuit, and the details are saltier than a bucket of fries. The folks who held PTLO shares between September 19, 2023, and May 4, 2026, are in the...

Continue Reading
Ontario Airport Braces for Holiday Travel Surge

Updated Category News Views 126

Gearing Up for a Thanksgiving Travel Boom Think Thanksgiving brings only turkey to the table? Down in Ontario, California, it's all about jet fuel and passenger counts. The Ontario International Airport (ONT) is where the skies are buzzing, forecasting over 227,000 passengers trying to soak up the holiday vibes by air. Compare that to the numbers when the local folks...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 203

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading

Top 5 Most Recently Viewed Articles

Tesla Faces Sales Challenges in Europe Amidst Controversies

Updated Category News Views 428

Tesla's Declining Sales in Key European Markets Tesla Inc (NASDAQ: TSLA) is facing significant sales declines in several European countries as reported in early 2025. These drops, drastic in some cases, seem to be a reflection of growing consumer dissatisfaction linked to CEO Elon Musk's heightened political involvement. The Impact of Elon Musk's Political Engagement As...

Continue Reading
How CareMessage's Wellness Copilot Enhances Diabetes Care

Updated Category News Views 141

Innovative Solutions for Diabetes Care Enhancement CareMessage, a pioneering non-profit organization, recently introduced the Wellness Copilot aimed at transforming diabetes management for vulnerable populations. The initiative comes at a crucial time when many healthcare systems are struggling to meet the demands of an ever-growing diabetic population across the country....

Continue Reading
MEDIROM Healthcare Technologies Announces Major Public Offering

Updated Category News Views 269

MEDIROM Healthcare Technologies Inc. Pricing Public Offering MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) has announced a significant step forward in its growth strategy by pricing a public offering of American Depositary Shares. This offering involves 2,860,000 shares priced at $1.75 each, totaling gross proceeds of around $5,000,000. The company is anticipating...

Continue Reading
Dreame's LEAPTIC Cube: Revolutionizing Action Cameras Today

Updated Category News Views 201

Dreame Unveils the LEAPTIC Cube: The Future of Action Cameras At CES 2026 in Las Vegas, Dreame Technology proudly introduced the LEAPTIC Cube, the company's first 8K AI action camera. This innovative release signifies a remarkable advancement in portable imaging, tailored for content creators, adventurers, and professionals seeking exceptional performance in a compact...

Continue Reading
Two Hands Corporation's Significant Shareholder Meeting Update

Updated Category News Views 294

Two Hands Corporation Reports on Special Meeting Outcomes Two Hands Corporation (CSE: TWOH.X) (OTC: TWOH) recently held a significant special meeting for its shareholders. This gathering served as a platform to discuss vital changes affecting the company's structure and stock distribution. Highlights from the Special Meeting During the meeting, shareholders voted to...

Continue Reading